Skip to main content
. 2011 Feb 28;2(3):493–498. doi: 10.3892/ol.2011.260

Table II.

Efficacy and toxicities in first-line FOLFOX4.

First-line result, % (95% CI)
 Objective response rate 31.4 (16.1–46.7%)
 Disease control rate 62.8 (46.8–78.8%)
 Median PFS in months 6.0 (5.4–6.5)
 Range 2.8–10.5
Reasons for discontinuing treatment, (n, %)
 Disease progression 25 (71.4)
 Neurotoxicity 3 (8.6)
 Allergy 7 (20.0)
Hematological toxicity (grade ≥3), (n, %)
 Leukopenia 4 (11.4)
 Neutropenia 20 (57.1)
 Anemia 1 (2.8)
 Febrile neutropenia 1 (2.8)

CI, confidence interval; PFS, progression-free survival.